1787: Clinical Advancement of a Cancer Vaccine in Dogs
Grant Status: Open
AbstractCanine lymphoma is the most common blood-based cancer in dogs with an estimated annual incidence of 30/100,000. Chemotherapy induces remission in 75-85% of patients; however, the majority of patients relapse with drug-resistant lymphoma within 8-10 months of diagnosis and most dogs die of their disease shortly thereafter. Cell-based vaccine strategies that stimulate anti-tumor immunity have shown promise in the treatment of many different cancer types including non-Hodgkin's lymphoma (NHL) in humans. In a previous study Dr. Mason developed a cell-based vaccine to induce anti-tumor immunity in dogs with NHL. Initial studies were hopeful as this early vaccine significantly prolonged second remission duration and overall survival, but ultimately the vaccine did not prevent relapse. These early findings suggest that while the lymphoma vaccine stimulated anti-tumor immunity it will require immunological boosting to achieve prolonged cancer-free survival. In the current study, Dr. Mason will optimize her cell-based vaccine approach to induce functional, long lasting tumor-specific immune responses that will prevent relapse and prolong survival in dogs with NHL.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.